Medicine
Lunsumio 30 mg/30 mL injection
Lunsumio 30 mg/30 mL injection is a prescription medicine containing Mosunetuzumab for intravenous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Mosunetuzumab
- Brand
- Lunsumio
- Strength
- 30 mg/30 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 30 mL
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX25 Mosunetuzumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 December 2022
- Identifiers
- RxCUI 2625129, 2625135, 2625137 +1DailyMed set ID 2ef0cf38-101c-4681-98fe-c05dc9ead443NDC 50242-142Application BLA761263
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 30 mL in 1 vial | 50242-142-01 | Genentech | 22 December 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Mosunetuzumab
Clinical summary
Mosunetuzumab is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. It is available as injection for intravenous and subcutaneous use. MedsAcross supplies Mosunetuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MosunetuzumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lunsumio Velo prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Lunsumio: European public assessment report (EPAR) · European Medicines Agency
Need Lunsumio 30 mg/30 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.